<DOC>
	<DOCNO>NCT00396955</DOCNO>
	<brief_summary>Objectives : Primary : To assess efficacy safety PLA-695 subject active osteoarthritis ( OA ) knee . Secondary : To determine pharmacokinetics ( PK ) pharmacodynamics ( PD ) PLA-695 among dose level . To assess health outcome measure . To assess effect PLA-695 biomarkers related clinical response . To assess PLA-695 exposure-response relationship PD , efficacy , safety measure . To assess pharmacogenomics ( PGX ) analysis OA .</brief_summary>
	<brief_title>A Study Comparing 4 Dose Regimens PLA-695 , Naproxen , Placebo In Subjects With Osteoarthritis Of The Knee</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , double-dummy , parallel , placebo- positive-control ( naproxen ) , dose-ranging study ass efficacy safety 3 oral dos PLA-695 administer QD 1 dose PLA-695 administer BID 6 week . Subjects randomize 1 6 treatment group : PLA-695 50 mg , 200 mg , 400 mg QD , PLA-695 200 mg BID , placebo , naproxen 500 mg BID . Subjects undergo washout period 2 14 day . The number day washout determine pre-study NSAID subject . Subjects washout previous therapy increase sign symptom OA randomly assign receive PLA-695 .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>The main inclusion criterion list , additional inclusion criterion protocol . Men woman 50 75 year age . Women must nonchildbearing potential . Sexually active men surgically sterile must agree commit use barrier contraception study least 12 week last dose PLA . Diagnosed idiopathic OA knee least 3 month duration accordance [ 1986 ] American College Rheumatology ( ACR ) clinical radiographic criterion : knee pain , presence osteophyte , one following : age &gt; 50 year , crepitus , morning stiffness &lt; 30 minute . Radiographic confirmation OA target joint ( weightbearing anteroposterior lateral view ) within 1 year screening . Must currently treat OA stable daily dose 1 NSAID , include COX2 inhibitor , exceed maximum recommend dose product label , take prescribed physician , start least 4 week screen visit . These main exclusion criterion study . Additional exclusion include protocol . History suspect current esophageal gastrointestinal bleeding , ulcer , obstruction , perforation , pancreatitis . Grade 4 severity KellgrenLawrence Scale screen target knee radiograph . Any significant cardiovascular , hematologic , blood dyscrasia , endocrine , respiratory , neurologic , psychiatric , metabolic , immunologic , infectious , hepatic , renal condition investigator considers detrimental subject 's participate study may prevent successful completion study . Any clinically significant laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>arthritis</keyword>
	<keyword>pain</keyword>
</DOC>